multivalent group b streptococcus vaccine
Vaccineexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jun 5, 2017 (NCT03170609)
Timeline
Indications
Mechanism of action
- Streptococcus sp. group BImmunity, active
Streptococcus sp. group B immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- multivalent group b streptococcus vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07160244 | Phase 3 | Aug 25, 2025 | Pfizer |
| NCT03765073 | Phase 2 | Jan 14, 2019 | Pfizer |
| NCT03170609 | Phase 2 | Jun 5, 2017 | Pfizer |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 3 | 3 | 2 | 2017 |
1 organizations
Page 1 / 1